{"id":"W2588521106","doi":"10.1093/annonc/mdw332.04","title":"Brigatinib (BRG) in Crizotinib (CRZ)-Refractory ALK+ Non–Small Cell Lung Cancer (NSCLC): efficacy and safety results from ALTA, a pivotal randomized phase 2 Trial","year":2016,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Crizotinib; Clinical endpoint; Internal medicine; ALK inhibitor; Adverse effect; Phases of clinical research; non-small cell lung cancer (NSCLC); Response Evaluation Criteria in Solid Tumors; Lung cancer; Randomized controlled trial; Oncology; Refractory (planetary science); Gastroenterology; Surgery; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001932185,0.0015897,0.002432957,0.0005090098,0.0003566111,0.001326572,0.0008751638,0.001291128,0.0041418],"category_scores_gemma":[0.001422995,0.0005559013,0.001799743,0.000576689,0.0009480787,0.001328696,0.0003922448,0.003696862,0.001453162],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0009737242,"about_ca_system_score_gemma":0.001017663,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00148558,"about_ca_topic_score_gemma":0.005430216,"domain_scores_codex":[0.999507,0.0002230034,0.00003284658,0.000078154,0.00005398654,0.0001049911],"domain_scores_gemma":[0.9994239,0.0001227458,0.0001413721,0.00004620149,0.0000443577,0.0002215236],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8493069,0.005345496,0.003435355,0.002040509,0.003547243,0.000163905,0.0001239369,0.001217181,0.01382401,0.0003761316,0.007555144,0.1130642],"study_design_scores_gemma":[0.9255551,0.05858627,0.008322232,0.0001028922,0.001690854,0.0002399619,0.00005848312,0.0008447618,0.001213924,0.0002791529,0.003066194,0.0000402476],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9684475,0.02111651,0.0004167463,0.001973182,0.0004600067,0.001076941,0.001834424,0.0004000764,0.004274574],"genre_scores_gemma":[0.9813622,0.009024643,0.0009558781,0.001972806,0.0002929643,0.0006644643,0.002854498,0.00005066092,0.002821989],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0041418,"threshold_uncertainty_score":0.01385576,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0444454593184638,"score_gpt":0.4245253480343797,"score_spread":0.3800798887159159,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}